Skip to main content

Advertisement

Table 1 Baseline demographics and disease characteristics

From: The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial

  Saxagliptin* Control*
N 21 21
Age (years), mean ± SD 58.3 ± 5.7 56.4 ± 8.5
Female, n (%) 11 (52%) 7 (33%)
Race, n (%)
 African American 15 (71%) 13 (62%)
 White 5 (24%) 6 (29%)
 Other 1 (5%) 2 (10%)
Weight (lbs), mean ± SD 202.7 ± 24.5 202.3 ± 38.7
BMI (kg/m2), mean ± SD 32.3 ± 4.2 31.5 ± 4.8
Duration of diabetes (years), mean ± SD 3.7 ± 2.4 3.5 ± 1.8
HbA1C mean ± SD 7.0 ± 0.8 6.6 ± 0.5
Fasting glucose (mg/dL), mean ± SD 127.4 ± 35.9 114.8 ± 25.0
eGFR (mL/min/1.73), mean ± SD 98.9 ± 14.5 93.7 ± 16.7
  1. * No significant differences were observed